Traditional Chinese Medicine manufacturer Weikang Bio-Technology said it will launch three new therapeutics during the first quarter of 2011. Weikang expects that its new products have the potential to add up to approximately $3.1 million in revenue and up to approximately $1.1 million in net income combined in 2011.

"We are pleased to be able to regularly launch high margin new products that enable us to continue expanding our market penetration and future revenue and net income growth," commented Mr Yin Wang, chairman & CEO of Weikang Bio-Technology. "Over the past few years ,our R&D team have been extremely focused on developing a strong pipeline of high-quality, therapeutics to address today's important health issues. In addition, we ensure that our products are produced using the highest quality of natural ingredients and advanced processing technologies for maximum effectiveness."

The new therapeutics have been approved by the State Food and Drug Administration (SFDA). A brief description of the new therapeutics expected to be launched in first quarter 2011 is listed below:

TiangFang

•Shouwu Long Life is primarily used to strengthen kidney and cardiovascular system, as well as improve blood circulation in mature adults. It is also beneficial in treating dizziness, ringing in the ears, forgetfulness, and early graying

•Lysozyme Buccal is an antibiotic tablet which can effectively treat the acute and chronic pharyngitis, upper respiratory infections and ulceration symptoms.

Rongrun

•Ha Ge Jiao Lan is used to treat symptoms associated with menopause as well as increase youthful vitality and balance hormones.